{"filing":{"accession_number":"0001193125-26-254581","cik":"0001540171","ticker":"AVLN","company_name":"Avalyn Pharma Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"ck0001540171-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/ck0001540171-20260603.htm"},"events":[{"id":7129,"run_id":6255,"accession_number":"0001193125-26-254581","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing explicitly discloses financial results for the quarter ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides the registrant's periodic financial performance.","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3927,"accession_number":"0001193125-26-254581","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing explicitly discloses financial results for the quarter ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides the registrant's periodic financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:14.265761+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3927,"accession_number":"0001193125-26-254581","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing explicitly discloses financial results for the quarter ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides the registrant's periodic financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:21:14.265761+00:00","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-06-03"}]}